Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for sharing Gaffer.
Goddammit, sarcasm wins again, I have to get better at reading what the fonts are really trying to say.
Sorry my sarcasm was not more noticeable.
What's the suprise supposed to be?
Died from greed and failure?
What happend, did Bumka die from covid?
So very true eom
Bunka strikes us as not having the balls or decency to meet directly with his retail investors in person or via video. Bunka is abusing the system with his high comp package against little results frankly. He should be replaced as CEO and lets have someone who can actually close a big deal or two. Disgusted.
I agree with the visit to Bunka and a face to face. Where does he live?
Until the stock price goes over $30 and continues to stay there, Bunka and Docherty should reduce there Salaries. Pharma companies have a different valuations, but incase of LEXX with so many streams, why none of them are willing to loan even $5-10 mil. So if the technology/IP is so promising, by now one of these Pharma companies would shown some level of interest.
Forget Pharma, why has none of the bigger Alcohol, or Tobacco companies not shown any interest.
Ted Ohashi still bullish on Lexaria. Pg. 15
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_bc6d1a0b6446483797e254f3c5ebb0c3.pdf
One of the reasons I am so enthusiastic about the prospects for Lexaria Bioscience (NASDAQ:
LEXX) (NASDAQ: LEXXW) is they are conducting a wide range of tests of its DehydraTECH™ technology. In the six years or so that I have been following LEXX, DehydraTECH™ has proven to be a very
robust technology and has consistently returned positive results. In the past year, with LEXX listed on the
NASDAQ, we have seen the market respond with some vigor to positive results from testing. However,
as the market assessed the incremental increase in market cap with each result, it was not able to accumulate that value over time. As a result, since the NASDAQ listing, the shares have been up until the
stock price dropped during tax loss selling at year end.
Looking ahead, I think as each prospective application is supported by more data, the market will place a
cumulative valuation on the shares. In addition, we shouldn’t ignore the possibility of a significant breakthrough result that might come at any time.
Here is a summary of the tests completed in 2021 and scheduled for 2022.
16
2021/2022 Study Program
? HYPER-A21-1 - Rodent study completed (n=10) demonstrating significant enhancement in CBD delivery using DehydraTECH - Up to 2,178% more CBD delivered into bloodstream and up to 1,737%
more CBD delivered into brain tissue.
? HYPER-A21-2 - Rodent study completed (n=10) demonstrating strongest CBD absorption results
ever recorded using DehydraTECH - New formulation delivers up to 2,708% more CBD into bloodstream
? HYPER-H21-1 – Human clinical study (n=24) evidencing a rapid and sustained drop in blood pressure
with DehydraTECH-CBD and excellent tolerability
? HYPER-H21-2 - Human clinical study (n=16) Hypoxic Pulmonary Vasoconstriction study; evidences
up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to
placebo and confirms DehydraTECH-CBD reduces arterial stiffness
? VIRAL-C21-3 - In vitro screening assay completed using a primate cell line, VERO-E6, determined
remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19
SARS-CoV-2 virus
? VIRAL-A20-2 - Rodent study completed (n=40) DehydraTECH enables up to three-fold increase in
oral delivery of antiviral drugs, Remdesivir and Ebastine
? VIRAL-MC21-1 - Successfully confirmed Lexaria's molecular characterization study objectives,
demonstrating DehydraTECH processing and formulation technology does not create a covalently
bonded new molecular entity (NME) and that each drug tested remained stable and did not undergo
change in chemical structure. These findings are strongly supportive of accelerated regulatory filings
such as the 505(b)(2) pathway permitted by the Food and Drug Administration (FDA) and other international regulators
? VIRAL-A20-3 - Rodent PK study completed (n=20) demonstrating significant enhancement in antiviral drug delivery using DehydraTECH-enabled Colchicine. Possible benefits for treating SARS-CoV2/COVID-19 and mRNA vaccine side effects
? NIC-A21-1 - DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls
The following studies are part of approximately 12 applied R&D programs planned for 2022 (tentative start
dates are included):
? HOR-A22-1: April 2022. This PK study will evaluate the ability of DehydraTECH to enhance the delivery characteristics of estrogen. Estrogen helps to control the menstrual cycle but also controls cholesterol and protects bone health. The hormone replacement market is estimated at $46.5 billion in
2027.
? DEM-A22-1: July 2022. This efficacy study will evaluate DehydraTECH-CBD with and without nicotine
for the potential treatment of dementia. Alzheimer's disease is the most common form of dementia
and accounts for at least 60% of all cases, and nicotine is already showing promising results related
to Alzheimer's treatment. An estimated 55 million people worldwide are currently affected by dementia, with 78 million expected to be living with some form of dementia by 2030. The dementia drug
treatment market is estimated at $19.6 billion in 2026.
17
? RHEUM-A22-1: October 2022. This efficacy study will focus on the ability of DehydraTECH-CBD to
potentially affect treatment of rheumatoid disease. Given CBD's postulated efficacy related to inflammation, Lexaria will explore a possible role for CBD in this area of investigation. Rheumatic diseases
are autoimmune and inflammatory diseases that cause the immune system to attack joints, bones,
muscles and organs. There are over 100 rheumatic diseases including Fibromyalgia, Lupus, Osteoarthritis, Rheumatoid Arthritis and more. The Rheumatoid Arthritis therapeutics market alone is expected to be over $30 billion per year by 2025.
? DIAB-A22-1: November, 2022. This efficacy study will explore the ability of DehydraTECH-CBD to
potentially affect treatment of diabetes. Diabetes prevents the body from making enough insulin, r
esulting in abnormal blood sugar levels. Diabetes is the 7
th largest cause of death in the US and there
is currently no cure. Investigation of CBD related to diabetes is in early stages, though there are
some areas of ongoing investigation. CBD has shown some ability to reduce the incidence of diabetes
in mice. The prescription drug market used to treat diabetes is expected to be a $77.9 billion global
market in 2024.
Conclusion: with a patented technology that improves the way active pharmaceutical ingredients enter
the bloodstream and its listing on the NASDAQ early this year, Lexaria Bioscience (NASDAQ: LEXX,
LEXXW) has successfully disassociated itself from
the cannabis industry. Thus,
while the cannabis
group is down
sharply since February 2021, LEXX has been able to maintain its value in that time frame. Of course, cannabinoids remain
important to LEXX but now as an active pharmaceutical ingredient. To give you a sense of the breadth of
areas being investigated, consider the following list: dementia (Alzheimer’s), diabetes, heart disease, hormone replacement, hypertension, Lupus, oral nicotine, Osteoarthritis, and rheumatoid diseases (Fibromyalgia, Rheumatoid Arthritis). The work is fully funded through all of 2022 and the first half of 2023. As a
result, I believe LEXX and LEXXW holders will have several event related positive moves in the market
in 2022. I suggest every growth portfolio should earn LEXX and/or LEXXW
CEO Chris Bunka is quite simply useless at this point (and has been for a long time now). He needs to do the right thing and step aside for a more capable CEO.
"Bumka"...! XD
I don't expect to get a penny back from that lying POS but would like to tell him to his face and hope that he gets everything I believe he deserves - measured twice and overflowing.
All these lies about this and that let's all Pay bumka a visit and try and get him to sell some of his assets to pay us back, who's in?
It appears that Cannadips CBD pouches are a complete bust. Production has stopped and they are stuck with unsold inventory. People are not interested in getting their CBD by sucking on a pouch it seems. I think that Cannadips will have more success with their THC pouches, but of course we won't get any revenue from that product.
Revenue
Product revenues of $7k and licensing usage fees of $Nil during period ended November 30, 2021, constitute a significant decline in intermediate product sales and related licensing
usage fees. Our primary customer in the B2B product revenue stream has been delayed in chainstore rollouts due resulting in overstocked inventory and as such there was no
manufacturing & sales of new inventory for this licensee for the quarter ended November 30, 2021.A number of our other licensees are experiencing suspended or curtailed business
activities due to the impact of COVID19 on markets and consumer spending. The abilities of other licensees to generate ongoing sales, thereby increasing usage fees are expected to
increase as the effects of the pandemic are eventually diminished. We have continued strong interest in our intermediate products but cannot predict how long the pandemic will affect
purchasing decisions of retail customers that ultimately affect the consumer product manufacturers that utilize our intermediate products. Nor can we predict when recovery of the
general economy will translate into increasing licensing or usage revenues.
I know eh, what a goddamn joke lexaria has become.
Media campaign?? just more Bunko BS.
Bunko and Dr John R$D get $356k and $310 plus stock options, 2% percent of the sale of a division...bleeding Lexy dry and accomplishing nothing but burning the cash from the last raise. ...unfortunately the BOD will not do anything but line their own pockets. Bunko has no credibility in the market at this time. I have come to terms with this being an investment disaster on my part.
Quarterly Report is out and it's a disaster, revenue has cratered to only $13,880.00 and net loss has soared to $2,000,000. No wonder they waited till long after the bell on a Friday to release this.
http://www.stockwatch.com/News/Sedardoc/5016611.pdf
CEO Chris Bunka is proving ineffective so it is certainly time to step aside. This is what happens in the real world.
The CEO Chris Bunka is very much in need of replacing. If the Lexaria tech is that good, a more capable CEO would broker deals. All we shareholders are seeing is Bunka reaping a massive salary which is not yet justified frankly. #bunkaneedstostepdown
Waiting to come to terms with the losses incurred. Dead money like LEXX
Just like bunka
Thanks, Sanderson. I guess Shawking is right, because I haven't heard anything. I thought I might get a response, because I was polite. Guess that didn't do the trick.
A small fintech company I worked at for ~4 years got acquired a few days ago.
The CEO is a mutual acquaintance of both myself and a good buddy of mine who's worked in investment banking for many years now; so, my buddy's "kept tabs" on them.
I expressed my surprise at the acquisition - when I left, the company had been in business for about 10 years, and was yet to become profitable. Buddy immediately came back with "they got acquired because of their IP - not their revenue numbers."
For what [little] it's worth, I suspect that:
1. DehydraTECH is legit - and possibly paradigm-shifting - bioavailability technology.
2. Bunka's perfectly happy being exactly where he is [in life].
Accordingly, my guess is that Bunka is content with Lexaria just "riding the research wave" - i.e., banking more and more IP - until either (a) he just decides he's bored / tired / whatever of it all one morning, or (b) someone makes him an offer he cannot refuse.
This is all my $0.02, as usual - I "know" nothing.
Both these guys are way overpaid ($356k and $310k) plus, stock options, 2% piece of the sale of a sub, up to 50% bonuses --- results to date --- lots of compensation --- success -- not much. In too deep to just walk away, nothing I can so about their comp/firing them - will just wait to see if Bunka can complete a "hail Mary" pass. Appreciate the postings here...GLTA
I don't know if this - i.e., filings - qualifies as "hearing back"... but it looks like Chris & John just got re-upped:
https://www.sec.gov/Archives/edgar/data/1348362/000164033422000015/0001640334-22-000015-index.htm
Kevin, good luck.
Complaining is unlikely to draw a response from IR.
I wrote to IR on Friday, asking them politely if they have any explanation for why the lack of more investors after the reverse split, and also mentioned that people have questions about Bunka's salary given the lack of performance. Will let people know if and when I hear back.
Salary's of startups like LEXX should not be more than $120-180k, especially knowing that he failed to bring Institutional invested that he touted prior to RS, he does not deserve such high salary, only when the share price goes back to $50 and stays there for more than 10 days is when he can claim $300k base salary.
They registered 1.6 mil warrants and it means they expecting the stock to go up substantially and expecting conversion of those @6.50, the min stock price for that has to be $9 to $12 for little bit profit. This is the last chance for someone to get in at bottom.
This is great news; we are only down 3.5% so far today. Just think what it could have been.
I think Bunka said if we do another reverse split he has people and institution ready to buy...maybe 60 to one and not that old 30 to one that just didn't work...and just like that we are at $200+.
2022 top priorities for Lexaria...listed in order of importance
1. Protect Bunka's compensation
2. Protect Bunka's compensation
3. See 1 & 2 above.
Wow, another god damn study
Accumulate what? More loses when it gets kicked back to the OTC
Time to accumulate again eh?
Management is pathetic here. Starts at the top with bunka. He played everyone. Look at his salary and tell me how that is justified????
insert-text-here
Introducing Elev8 - Dehydr8 Michigan’s brand powered by Hill Avenue’s fast-acting DehydraTECH™? technology.
Happy Holidays and good health in the New Year to all eom
Followers
|
220
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
34635
|
Created
|
10/02/07
|
Type
|
Free
|
Moderators |
Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.
Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.
Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners
Effects are felt within 15-20 min vs. 60-120 min.
Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.
Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.
Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:
Lexaria Bioscience Corp. (“Lexaria”) has formed the Lexaria Nicotine Corp. as its exclusive worldwide nicotine business unit. More than 89% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year around the world are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention. Of note: “…it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that cause illness and death.” (U.K. National Institute for Health and Care Excellence [NICE]). As many as 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve-month period. Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patented DehydraTECH technology in common food and consumer product formats, could shift demand away from smoking cigarettes. However, ingestion of nicotine is challenging because it is poorly tolerated by the human gastrointestinal system and then significantly metabolized by the liver, thereby diminishing its overall effectiveness through edibles. Lexaria’s DehydraTECH technology offers a means to formulate ingestible product formats of nicotine and/or its analogs with higher bioavailability performance possibilities due to the benefits of our technology.
Lexaria is developing a patent suite with supporting intellectual property in the pharmaceutical sector that will supply significant long-term strategic growth potential. Lexaria Pharmaceutical Corp. is the 100%-owned subsidiary that has obtained exclusive worldwide rights to Lexaria’s patent portfolio related to pharmaceutical applications. Currently within this business unit resides the IP for Non-Steroidal Anti-Inflammatories (NSAIDs), Vitamins, hormone treatments utilizing estrogen or testosterone, phosphodiesterase inhibitors (PDE5). Additional molecules of interest could be added to this unit over time.
According to Statista.com, the global pharma industry was worth $1,105 billion in 2016, and the US pharma industry alone spent over $71 billion in 2017 on R&D: a larger R&D expenditure than the entire gross revenues of many other business sectors.. Lexaria Pharmaceutical Corp. is implementing a strategy of reinforcing its IP-suite to sufficient degree to begin partnering within this dynamic industry.
The Lexaria Hemp Co. holds exclusive global rights to the Lexaria patent portfolio related to hemp-based applications. Lexaria’s DehydraTECH technology is designed to deliver functional ingredients within hemp in oral product formats with significantly enhanced palatability, speed of effectiveness and potency as a viable and healthier alternative to conventional inhalational (i.e. smoking or vaping) administration practices. Extensively evaluated through invivo, invitro, and human clinical studies, one of the most extensive databases in the world has been collected by Lexaria related to hemp-based ingredients empowered with our DehydraTECH technology. In 2018, the World Anti Doping Agency (WADA) for the first time ever exempted cannabidiol from hemp from its list of restricted substances on its International Standards Prohibited List of substances.
Lexaria CanPharm Corp, a Canadian corporation, owns exclusive global rights to Lexaria’s intellectual property as it is applied to psychotropic bioactive molecules that act upon human CB1 and CB2 receptors in those areas of the world where it is permissible to do so. Substances that act upon these receptors and systems in the human body that affect pain, inflammation, anxiety and depression, and have also been shown to have utility against cancer and neurodegenerative conditions. Lexaria’s ground-breaking 2018 research that proved many-fold improvements in delivering an active ingredient across the blood-brain-barrier could have disruptive potential within this business sector as well as all others where Lexaria is active.
The safety and effectiveness of Lexaria’s DehydraTECH™ technology has been studied in a series of controlled and well designed in vitro and in vivo human focus studies, examining factors such as total bioabsorption directly and indirectly through surrogate biomarkers, time to onset of effectiveness, flavor appeal and quality of effectiveness. Studies to-date have focused on cannabinoid applications where Lexaria is most advanced commercially, although research is underway for the other bioactive compounds named in Lexaria’s patent portfolio and described under Commercial Applications.
Pre-Clinical Research into Lexaria’s DehydraTECH™
An in vitro absorption study was performed to assess unidirectional CBD permeability using a human epi-intestinal tissue model with various formulations in the presence of simulated intestinal fluid. The study was designed to, as closely as possible, mimic intestinal absorption as it would occur in a live subject. Samples of Lexaria’s commercially available CBD-fortified ViPova™ black tea were administered in the model compared with concentration-matched CBD control preparations that lacked Lexaria’s patented formulation and process enhancements. The study showed as much as a 499% improvement, on average, in intestinal tissue permeability with the ViPova™ black tea formulation relative to a concentration-matched CBD control preparation without any Lexaria technology enhancements. The study also showed a 325% improvement, on average, in intestinal tissue permeability comparing the ViPova™ black tea preparation to a concentration-matched CBD control preparation that utilized Lexaria`s dehydration synthesis processing methodology but lacked its fatty acid ingredient incorporation, demonstrating the power of the Lexaria technology as a whole (see Figure 1).
Following this study, a series of independent, well designed, well controlled human focus studies were undertaken corroborating Lexaria’s in vitro performance findings. A study in healthy volunteers (n=6) suggested as much as a 5-10X increase in CBD absorption, which was assessed indirectly through measurement of the increase in salivary nitric oxide as a directly proportional surrogate biomarker, with onset of action in as little as 15-30 minutes. In all cases, the maximum increased level of salivary nitric oxide remained evident at the 60-minute end period of this particular test. Further testing is required to determine the full duration of elevated nitric oxide levels.
Thereafter, a blinded human focus study was conducted to evaluate the performance of THC-infused chocolates formulated using Lexaria’s DehydraTECH™ technology. This study compared the performance of the THC-infused chocolates powered by Lexaria’s technology to concentration matched THC-infused chocolates formulated using a commercial dextrin absorption enhancer. The subjects (n=12) that participated in this study indicated a clear preference on taste and overall effectiveness with the chocolates formulated using Lexaria’s technology, and onset of effectiveness was again observed very quickly, in as little as 15-20 minutes.
Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed.
DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:
DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.
Contact us today to speak about your licensing needs at ablanchard@lexariabioscience.com
Terms and rights associated with our licensing opportunities are discussed on an individual basis.
Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs. Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.
We will license our technology in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics. Customers are loyal to the improved performance of DehydraTECH based products.
DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of chemicals or intimidating, complex ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, gluten-free, and dairy free.
If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.
Masks taste/odor
Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners.
Reduces time of onset
Effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption
Increases bio-absorption by 2 – 10x, to equate or exceed that of other routes of administration like inhalational delivery.
Avoids first-pass liver metabolism
Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects. More recent testing in animals even demonstrated an ability to cross the blood-brain-barrier to a degree previously thought not possible.
Interview with CEO Chris Bunka
https://youtu.be/9bRSWYKIEL8
New Enhanced DehydraTECHTM formulation delivers 8X more CBD into blood and over 19X more CBD into brain tissue than standard industry formulations.
Kelowna, British Columbia – June 4, 2019 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a drug delivery platform innovator, has discovered improved performance characteristics of a new version of the DehydraTECHTM delivery platform initially suitable for use in solid oral dosage forms like capsules, tablets and pills for the pharmaceutical, medical, and supplement markets. Lexaria’s innovative use of a naturally sourced formulation enhancement more than doubles DehydraTECH’s absorption performance compared to previous DehydraTECH results demonstrated to-date. The Company has filed new patent applications related to the recent innovations.
BACKGROUND
On March 20, 2019 Lexaria announced it was beginning a series of animal studies with multiple objectives, including evaluating enhanced DehydraTECH formulations that might offer improved performance. Copious data streams have been generated from these tests and continue to be analyzed.
In this arm of animal study, Lexaria tested its DehydraTECH delivery technology with compounds postulated to behave in a synergistic fashion for enhancement of gastro-intestinal absorption, which resulted in significantly enhanced DehydraTECH performance (“Enhanced DehydraTECH”).
Of note, the new Enhanced DehydraTECH and its improved performance is separate and distinct from the nanotech improvement techniques recently announced by the Company.
TEST RESULTS
In each arm of the Lexaria animal studies, 10 male Sprague-Dawley rats were administered an identically sourced CBD at a rate of 25mg per kg of bodyweight. Delivery of CBD into the bloodstream was measured at 2; 4; 6; 8; 12; 15; 30; 45; and 60 minutes after dosing. DehydraTECH-enabled CBD was measurable in animal blood within 2 to 4 minutes after dosing.
On May 15, 2019 the Company reported that DehydraTECH achieved a CBD blood concentration level that was 475% more than a generic industry medium chain triglyceride (“MCT”) coconut-oil formulation 15 minutes after dosing. Today, the Company reports that Enhanced DehydraTECH led to 811% more CBD delivery into blood than generic industry MCT coconut-oil formulations (p=0.00008); and 110% more CBD into blood than DehydraTECH in its traditional format (p=0.02).
Also of note is that both traditional DehydraTECH and Enhanced DehyraTECH delivered maximum blood concentration levels prior to the 60-minute end-of-test, with levels tapering off thereafter. The DehydraTECH technology therefore demonstrates both fast onset and fast offset as tested which is of interest for dose titration purposes when repeated dosing is desired.
CONCLUSION
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout 2019 to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |